Home

Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd. (Bioceltran), a Korea based company. Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from Korea (Madenco Biosciences Inc.). Quest is also developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications (AmrutBio).

Quest Chart Feb 2017

Link to Quest PharmaTech Inc. Fact Sheet

Press releases 2017

May 24, 2017
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2017
Madenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin™ Serum for Anti-Aging

May 9, 2017
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

May 4, 2017
Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief

February 15, 2017
Quest PharmaTech Announces Results from its 2017 AGM

Press releases 2016

December 7, 2016
OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

November 29, 2016
OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

November 14, 2016
Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches
Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada

November 2, 2016
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

October 28, 2016
Quest PharmaTech Inc. Announces Change of Auditor

October 20, 2016
Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

September 16, 2016
Quest PharmaTech Inc. Amends Warrant Terms

September 6, 2016
Quest PharmaTech Inc. Retains Haft Group for Financial Services

August 5, 2016
Quest PharmaTech Announces Filling of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016

Mar 22, 2016
Quest PharmaTech’s Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Press releases 2015

Dec 10, 2015
Quest PharmaTech Receives U.S. $2 Million for its ImmunoPhotodynamic Therapy Assets

Dec 1, 2015
Quest PharmaTech Announces Results from its 2015 AGM